RxDoctor Payments Data

Brian Wong, MD

Neurology · Hartford, CTNPI 1336588482

Payments from drug & device makers

$15,830in general payments, 2019–2025

Across 391 payments — averaging $40.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$5K
  • Novartis$4K
  • AbbVie$3K
  • Pfizer$699
  • Genentech USA, Inc.$395
  • Amgen$374
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$2902%
  • Speaking & faculty fees$4,64029%
  • Travel & lodging$5313%
  • Food & beverage$7,54348%
  • Education$1561%
  • Gifts$2,67017%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,830 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$21,078
Medicare patients
84
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab82$841,794
MayzentSiponimod27$247,263
Nurtec OdtRimegepant Sulfate21$31,320
Dalfampridine ErDalfampridine42$16,588
Emgality PenGalcanezumab-Gnlm22$15,444
Gabapentin158$4,255
Baclofen166$4,052
Tizanidine Hcl59$2,596
Teriflunomide22$2,434
Pregabalin91$1,956
Ropinirole ErRopinirole Hcl14$1,705
Duloxetine Hcl28$964
Oxybutynin Chloride ErOxybutynin Chloride32$811
Modafinil23$789
Nortriptyline Hcl38$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$4,412$247,26327 claims
PfizerNurtec Odt$699$31,32021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →